biotech company polyrizon ltd filed for an initial public offering with the us securities and exchange commission on wednesday the company said it plans to offer units in its ipo which will consist of one ordinary share and two warrants each for the purpose of buying one ordinary share the company didnt give an expected size for its ipo nor did it provide an anticipated price range the company said it is developing medical device hydrogels delivered in the form of nasal sprays that can provide a barrier against viruses and allergens polyrizon which has headquarters in israel said it applied to list its shares and warrants on the nasdaq capital market aegis capital corp is listed as the offerings sole bookrunning manager